A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Ulixertinib (Primary)
- Indications Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes; Pancreatic cancer
- Focus Pharmacokinetics
- Sponsors BioMed Valley Discoveries
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 03 Feb 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Dec 2016 New trial record